Sacral neuromodulation is becoming well known as a new, minimally invasive treatment for functional lower urinary tract disorders. Sacral neuromodulation is a minimally invasive treatment between conservative treatments (behavioral, pharmacological, theoretical) and highly invasive surgical treatments. It forms a transitional space between conservative treatment and major surgery, i.e. it does not have the high recurrence rate of conservative treatment or the risk of numerous serious complications of major surgery, the method is minimally invasive, reversible, can be combined with other treatments, can be terminated at any time, etc. In addition, even if the treatment fails, it does not affect the continuation of other treatments. This article focuses on the efficacy and complications of sacral neuromodulation in the treatment of functional pelvic floor disorders. Functional pelvic floor disorders are a difficult disease to treat in urology (as well as in obstetrics and gynecology and anorectal surgery). In the field of urology, the disease has various manifestations: urinary frequency, urgency, urge incontinence, “dyspareunia” with a feeling of incomplete urination, pelvic floor pain, and large amounts of residual urine and even urinary retention. The majority of people start with conservative treatment: various medications, behavioral and physical therapy, but less than 40% of patients are effective and the rest have poor results and satisfaction. The long visit to the doctor makes the patient economically and socially burdened, unable to tolerate the side effects of various medications, losing confidence in themselves and even in the doctor, and many patients develop depression and even suicidal tendencies. The etiology of functional pelvic floor disorders is not well understood, but different literature reveals that the pelvic floor muscles and external sphincter have a large proportion in affecting bladder and urethral function. Under normal conditions, during bladder filling, sphincter tone is increased, which inhibits voiding and completes urine storage. During voiding, the sphincter relaxes autonomously, thereby inducing normal voiding by contraction of the detrusor muscle. However, if the sphincter tone is too low during urine storage, it will induce an unstable contraction of the detrusor muscle, which will lead to urinary frequency, urinary urgency and urinary incontinence. On the contrary, if the sphincter tone is too strong and the pelvic floor tension is not relaxed, the normal contraction of the forceps will be inhibited, thus affecting urination and increasing residual urine or even urinary retention. Simply put, an imbalance in pelvic floor function in turn affects bladder function, resulting in the above symptoms. Sacral neuromodulation is to change the imbalance of pelvic floor function and bladder-urethral function through the integration of brain by weak electric current stimulation of sacral nerve roots, thus achieving the purpose of treating the disease. Sacral neuromodulation is also effective for pelvic floor pain (primary pain, prostatitis-related pain), interstitial cystitis and its resulting bladder pain, and painful concomitant dyspareunia. When intractable painful pelvic floor disorders are not responding well to all therapies tried, approximately 50-70% of patients who try sacral nerve therapy experience a 50% or greater improvement, and the results last for a long time in the vast majority of patients. This provides a good treatment option for such patients and can substantially improve the quality of life. I studied sacral neuromodulation in Finland and witnessed several patients with functional pelvic floor disorders undergoing permanent implantation of sacral neuromodulation in phase II, including: pelvic floor pain in interstitial cystitis, pelvic floor pain associated with intractable prostatitis, and patients with pelvic floor muscle tension + forced urinary muscle weakness + increased residual urination. All of these patients have shown good outcomes.